OMEGA PHARMA LIMITED

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

1. OMEGA PHARMA LIMITED 2012-10-05 → present
2. CHEFARO UK LIMITED 2002-08-22 → 2012-10-05
3. CHEFARO PROPRIETARIES LIMITED 1967-11-14 → 2002-08-22

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the period to 31 July 2026 and meet its liabilities as they fall due. The Company continues to and meet its day to day working capital requirements with its own assets and its ability to draw on an inter-company pooling arrangement including bank overdrafts drawn down on a short-term basis as part of long-term facilities, which are expected to continue. The Company has not been affected by the invasion of Ukraine, or the sanctions made against Russia as it does not have customers or suppliers in these countries. Neither has the Company been impacted on the increased geopolitical tensions across the globe. The Company produces a range of products which are seen as essentials and therefore resilient to the pressures on consumers budgets due to the cost-of-living increases in the last year. With regards to the US tariff changes this will have a low impact on the Company as it does not export to the US. The Company's financial forecasts, taking into consideration the current environment, show that it is expected to make an important and cash generative contribution to Perrigo's UK operations. Further, the Company will continue to receive support from its ultimate parent company for a period up to 31 July 2026. Accordingly, the directors of the company believe that it is appropriate to adopt the going concern basis in preparing the financial statements for a period up to 31 July 2026.”

Significant events

• “On 20 April 2022 the company was registered as guarantor to a fixed and floating loan facility granted by JP Morgan Chase Bank N.A. The loan facility was secured by the ultimate parent company Perrigo Company Plc to fund the acquisition of the French consumer healthcare company, HRA Pharma, from Astorg and Goldman Sachs Asset Management.”
• “On 2 June 2023, the Company's loan payable amounting to £61.8m to Ranir Holdings Limited (a fellow Perrigo Company Plc subsidiary) was forgiven by the latter's board of directors for nil consideration.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +39.3%

  £188,770,000 → £262,990,000

• Cash

  -65.4%

  £595,000 → £206,000

• Net assets

  -30.1%

  £92,758,000 → £64,835,000

• Employees

  +30%

  170 → 221

• Operating profit

  -19.3%

  £33,994,000 → £27,450,000

• Profit before tax

  -69.6%

  £98,530,000 → £29,979,000

• Wages

  +44.2%

  £12,043,000 → £17,368,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers